Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2026 and multi-year financial guidance, citing accelerating royalty revenue, expanding partnerships, and recent acquisitions that management says strengthen the company’s long-term growth profile.
The company released preliminary fiscal 2025 sales of $1.385 billion-$1.4 billion, up 36% to 38% year over year, with royalty revenues of $865 million-$870 million.
Looking ahead, Halozyme expects 2026 total revenue to grow between 23% and 30% year over year, driven primarily by royalties and API product sales.
Halozyme Therapeutics raises fiscal 2026 revenue guidance from the prior range of $1.43 billion-$1.53 billion to $1.71 billion-$1.81 billion.
Royalty revenue alone is projected at $1.13 billion to $1.17 billion, representing 30% to 35% growth and reaching the $1 billion mark a …